Amber Therapeutics closes $100 million Series A financing led by New Enterprise Associates to advance Amber-UI neuromodulation therapy for mixed urinary incontinence
Amber Therapeutics closes $100 million Series A financing led by New Enterprise Associates to advance Amber-UI neuromodulation therapy for mixed urinary incontinence
06/10/24, 7:14 AM
Location
londonMoney raised
$100 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
8 Vc, Oxford Science Enterprises, Intuitive Ventures, Lightstone Ventures, F Prime Capital, New Enterprise Associates
Amber Therapeutics, a UK-based medical technology company, has successfully closed its Series A financing round, raising a total of $100 million from leading healthcare and technology investors in the US and UK. The funding will be used to advance Amber-UI, a breakthrough adaptive neuromodulation therapy, towards US FDA approval to treat mixed urinary incontinence (MUI).
Company Info
Location
london, england, united kingdom
Additional Info
Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need. We have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation.
Amber UI is the company’s first therapy, aiming to restore normal physiological function in women suffering with mixed urinary incontinence.